All In Biotech

BLA 761061 · Janssen Biotech

Tremfya

Guselkumab · Injection · Interleukin-23 Antagonist

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 13, 2017

Approved uses

10

Original approval plus efficacy supplements

Registered trials

93

38 Phase 3, 30 recruiting

FAERS reports

38,224

9,624 serious, 482 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 20, 2026.

TREMFYA is an interleukin-23 antagonist indicated for the treatment of: adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. ( 1.2 ) adults with moderately to severely active ulcerative colitis. ( 1.3 ) adults with moderately to severely active Crohn's disease. ( 1.4 ) 1.1 Plaque Psoriasis TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. 1.3 Ulcerative Colitis TREMFYA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis. 1.4 Crohn's Disease TREMFYA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease.

Mechanism: Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Guselkumab inhibits the release of proinflammatory cytokines and chemokines.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TREMFYA · GUSELKUMAB 100MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Guselkumab" as an intervention, any sponsor and status, largest first.

All 93 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue12,395
  • accidental exposure to product3,707
  • drug ineffective2,587
  • needle issue2,480
  • psoriasis2,311
  • device issue2,150
  • device deployment issue1,793
  • device malfunction1,772
  • off label use1,650
  • product storage error1,218
  • device defective1,207
  • inappropriate schedule of product administration1,118

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
201784
20181,199
20192,087
20202,193
20213,115
20225,058
20235,778
20245,014
20256,820
20266,874

Recalls

1 FDA enforcement reports for this application.

  • Mar 9, 2021 · Class III · Terminated

    Temperature Abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tremfya* (Guselkumab)

2024 spending

$619M

Beneficiaries

10,848

46,079 claims

Per beneficiary

$57,041

$13,250.87 per unit

View as table
YearSpending
2020$167,392,578
2021$285,251,577
2022$439,124,671
2023$531,497,098
2024$618,784,543

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 247 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.